title: [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy associated toxicity in treatment of peritoneal carcinomatosis].
abstract: BACKGROUND
  Peritoneal carcinomatosis is a form of intra-abdominal dissemination of several tumours, which is associated with a poor prognosis. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is an alternative treatment. The aim of this study is to describe the toxicity associated with this procedure in patients with peritoneal carcinomatosis.
  
  
  METHODS
  We conducted a descriptive, retrospective, single-centre study, including all patients undergoing this procedure between December 2007 and January 2010. The following data were recorded: anthropometric data, personal and surgical events, indication, previous treatments, extent of carcinomatosis, intervention duration, hospital stay, and type of complications and/or adverse events following application of the multidisciplinary treatment.
  
  
  RESULTS
  We performed 46 interventions on 45 patients diagnosed with peritoneal carcinomatosis from different causes, mainly ovarian cancer (83%). Paclitaxel was the most-used drug (35 interventions). There was no associated mortality, the average intervention time was 6.4 hours and the average hospital stay 7 days. We recorded adverse effects for 42 procedures, being grade 3-4 in 28.3% of the patients. The severe adverse events were: 10.9% gastrointestinal, 10.9% infectious, 6.5% haemorrhage or bleeding, 6.5% medullary toxicity, 4.4% respiratory, 2.2% coagulation and 2.2% hepatobiliary disorders. One patient developed grade III neutropaenia, probably associated with cisplatin.
  
  
  CONCLUSIONS
  The morbidity and mortality is in line with the average of published studies, and has mainly been attributed to surgical complications. Toxicity data lower than other studies can be due to using more tolerable chemotherapy regimens, not including drug combinations and given that paclitaxel was the main drug.
authors.affiliation: Servicio de Farmacia, Hospital Universitario Virgen de la Arrixaca, Murcia, España.
authors.forename: A
authors.initials: A
authors.lastname: Mancebo-González
authors.forename: M S
authors.initials: MS
authors.lastname: Díaz-Carrasco
authors.forename: P
authors.initials: P
authors.lastname: Cascales-Campos
authors.forename: A
authors.initials: A
authors.lastname: de la Rubia
authors.forename: J
authors.initials: J
authors.lastname: Gil Martínez
mesh_terms: D000008:Abdominal Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D000328:Adult; D000368:Aged; D000886:Anthropometry; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols; D002277:Carcinoma / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D010478:Chemotherapy, Cancer, Regional Perfusion; D003131:Combined Modality Therapy; D004363:Drug Utilization; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000150:complications; D017239:Paclitaxel / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D012189:Retrospective Studies
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel